227 related articles for article (PubMed ID: 34642875)
1. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).
Horn A; Krist L; Lieb W; Montellano FA; Kohls M; Haas K; Gelbrich G; Bolay-Gehrig SJ; Morbach C; Reese JP; Störk S; Fricke J; Zoller T; Schmidt S; Triller P; Kretzler L; Rönnefarth M; Von Kalle C; Willich SN; Kurth F; Steinbeis F; Witzenrath M; Bahmer T; Hermes A; Krawczak M; Reinke L; Maetzler C; Franzenburg J; Enderle J; Flinspach A; Vehreschild J; Schons M; Illig T; Anton G; Ungethüm K; Finkenberg BC; Gehrig MT; Savaskan N; Heuschmann PU; Keil T; Schreiber S
Infection; 2021 Dec; 49(6):1277-1287. PubMed ID: 34642875
[TBL] [Abstract][Full Text] [Related]
2. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
Bahmer T; Borzikowsky C; Lieb W; Horn A; Krist L; Fricke J; Scheibenbogen C; Rabe KF; Maetzler W; Maetzler C; Laudien M; Frank D; Ballhausen S; Hermes A; Miljukov O; Haeusler KG; Mokhtari NEE; Witzenrath M; Vehreschild JJ; Krefting D; Pape D; Montellano FA; Kohls M; Morbach C; Störk S; Reese JP; Keil T; Heuschmann P; Krawczak M; Schreiber S;
EClinicalMedicine; 2022 Sep; 51():101549. PubMed ID: 35875815
[TBL] [Abstract][Full Text] [Related]
3. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
Schons M; Pilgram L; Reese JP; Stecher M; Anton G; Appel KS; Bahmer T; Bartschke A; Bellinghausen C; Bernemann I; Brechtel M; Brinkmann F; Brünn C; Dhillon C; Fiessler C; Geisler R; Hamelmann E; Hansch S; Hanses F; Hanß S; Herold S; Heyder R; Hofmann AL; Hopff SM; Horn A; Jakob C; Jiru-Hillmann S; Keil T; Khodamoradi Y; Kohls M; Kraus M; Krefting D; Kunze S; Kurth F; Lieb W; Lippert LJ; Lorbeer R; Lorenz-Depiereux B; Maetzler C; Miljukov O; Nauck M; Pape D; Püntmann V; Reinke L; Römmele C; Rudolph S; Sass J; Schäfer C; Schaller J; Schattschneider M; Scheer C; Scherer M; Schmidt S; Schmidt J; Seibel K; Stahl D; Steinbeis F; Störk S; Tauchert M; Tebbe JJ; Thibeault C; Toepfner N; Ungethüm K; Vadasz I; Valentin H; Wiedmann S; Zoller T; Nagel E; Krawczak M; von Kalle C; Illig T; Schreiber S; Witzenrath M; Heuschmann P; Vehreschild JJ;
Eur J Epidemiol; 2022 Aug; 37(8):849-870. PubMed ID: 35904671
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
5. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).
Steinbeis F; Thibeault C; Steinbrecher S; Ahlgrimm Y; Haack IA; August D; Balzuweit B; Bellinghausen C; Berger S; Chaplinskaya-Sobol I; Cornely O; Doeblin P; Endres M; Fink C; Finke C; Frank S; Hanß S; Hartung T; Hellmuth JC; Herold S; Heuschmann P; Heyckendorf J; Heyder R; Hippenstiel S; Hoffmann W; Kelle SU; Knape P; Koehler P; Kretzler L; Leistner DM; Lienau J; Lorbeer R; Lorenz-Depiereux B; Lüttke CD; Mai K; Merle U; Meyer-Arndt LA; Miljukov O; Muenchhoff M; Müller-Plathe M; Neuhann J; Neuhauser H; Nieters A; Otte C; Pape D; Pinto RM; Pley C; Pudszuhn A; Reuken P; Rieg S; Ritter P; Rohde G; Rönnefarth M; Ruzicka M; Schaller J; Schmidt A; Schmidt S; Schwachmeyer V; Schwanitz G; Seeger W; Stahl D; Stobäus N; Stubbe HC; Suttorp N; Temmesfeld B; Thun S; Triller P; Trinkmann F; Vadasz I; Valentin H; Vehreschild M; von Kalle C; von Lilienfeld-Toal M; Weber J; Welte T; Wildberg C; Wizimirski R; Zvork S; Sander LE; Vehreschild J; Zoller T; Kurth F; Witzenrath M
Infection; 2024 Feb; 52(1):93-104. PubMed ID: 37434025
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study.
Hartung TJ; Bahmer T; Chaplinskaya-Sobol I; Deckert J; Endres M; Franzpötter K; Geritz J; Haeusler KG; Hein G; Heuschmann PU; Hopff SM; Horn A; Keil T; Krawczak M; Krist L; Lieb W; Maetzler C; Montellano FA; Morbach C; Neumann C; Nürnberger C; Russ AK; Schmidbauer L; Schmidt S; Schreiber S; Steigerwald F; Störk S; Zoller T; Maetzler W; Finke C;
EClinicalMedicine; 2024 Mar; 69():102456. PubMed ID: 38333368
[TBL] [Abstract][Full Text] [Related]
8. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y; Strobl R; Apfelbacher C; Bahmer T; Geisler R; Heuschmann P; Horn A; Hoven H; Keil T; Krawczak M; Krist L; Lemhöfer C; Lieb W; Lorenz-Depiereux B; Mikolajczyk R; Montellano FA; Reese JP; Schreiber S; Skoetz N; Störk S; Vehreschild JJ; Witzenrath M; Grill E;
Infection; 2023 Dec; 51(6):1679-1694. PubMed ID: 37231313
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection in the first trimester and the risk of early miscarriage: a UK population-based prospective cohort study of 3041 pregnancies conceived during the pandemic.
Balachandren N; Davies MC; Hall JA; Stephenson JM; David AL; Barrett G; O'Neill HC; Ploubidis GB; Yasmin E; Mavrelos D
Hum Reprod; 2022 May; 37(6):1126-1133. PubMed ID: 35389480
[TBL] [Abstract][Full Text] [Related]
17. Return-to-work, disabilities and occupational health in the age of COVID-19.
Godeau D; Petit A; Richard I; Roquelaure Y; Descatha A
Scand J Work Environ Health; 2021 Jul; 47(5):408-409. PubMed ID: 34003294
[TBL] [Abstract][Full Text] [Related]
18. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study.
Balck A; Föh B; Borsche M; Rahmöller J; Vollstedt EJ; Waldeck F; Käding N; Twesten C; Mischnik A; Gillessen-Kaesbach G; Ehlers M; Sina C; Taube S; Busch H; Rupp J; Katalinic A; Klein C
BMC Public Health; 2022 Jul; 22(1):1305. PubMed ID: 35799167
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
20. Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19): structured summary of a study protocol for a randomised controlled trial.
Elder GJ; Alfonso-Miller P; Atkinson WCM; Santhi N; Ellis JG
Trials; 2020 Aug; 21(1):704. PubMed ID: 32771068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
